We have some exciting news to share! The Motley Fool UK has now become an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. We’ll be introducing a new name and brand over the coming weeks — we're very excited to share it with you and embark on this new chapter together!

Is it time to bail out of easyJet plc and buy GlaxoSmithKline plc instead?

A warning shot from easyJet plc (LON: EZJ) diverts attention to stable enterprises such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The main takeaway I get from today’s half-year report from airline operator easyJet (LSE: EZJ) is that net cash from operations is down 40% compared to the equivalent period last year and the firm made an earnings-per-share loss of 5.1p, which compares to a profit of 1.3p per share last year.

No wonder, then, at 1,500p, the shares are down around 14% since the beginning of 2016. Whichever way we dress it up, this isn’t a good result for easyJet and the firm’s shareholders.

Precarious profits

The outcome here demonstrates what a precarious juggling act it is to keep an airline profitable and growing. During the period, easyJet faced pressure on its business from justifiably skittish customers due to travel strikes and terror attacks on European capitals.

That’s the thing with an airline: we never know when a natural disaster such as an Icelandic volcano or man-made disasters such as war, conflict, strike, terrorism or commodity speculation will shoot down the firm’s profitability. But it gets worse than that. Airlines are also at the mercy of macroeconomic events making airline businesses and their shares among the most cyclical on the stock market.

That cyclicality has implications about how the market is likely to value businesses such as easyJet. The more mature a macro-cycle becomes, the lower I would expect easyJet’s valuation to be as the market tries to anticipate the next cyclical down-leg by discounting high earnings in the boom times.

Consumer demand strong

Right now, easyJet trades on a forward price-to-earnings (P/E) ratio of nine for the year to September 2017 and sports a twice-covered 4.7% dividend yield. I wouldn’t expect a higher valuation than that, so any further share price progress probably needs to come from business growth rather than from a valuation rerating.

Carolyn McCall, easyJet’s chief executive says: easyJet has delivered a robust financial performance during the half year despite the well-publicised external events. Underlying consumer demand has been strong with UK beach traffic providing a healthy start to the half and easyJet’s biggest-ever ski season helping to deliver increased passenger numbers and higher revenue during H1.

Okay. But it’s precisely when things are going at their best that we should expect a cyclical top, often followed by a descent into the next cyclical bottom. Nobody knows when the top will arrive, but I’m taking these first-half losses as a warning shot and now I’m avoiding easyJet shares.

A more robust business model

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) enjoys a more robust business model than easyJet’s. The stable nature of demand for medicines makes GlaxoSmithKline’s operation far less cyclical and keeps the cash taps flowing as consumers repeat purchase drugs.

Sure, the pharmaceutical industry had its challenges over patent expiry issues as once high-earning formulations lost exclusivity in the market and the firm saw a flood of generic competition erode profits. However, the company is moving on from that and hopes a new generation of blockbusters will return the firm to enduring growth.

City analysts following the firm expect earnings to grow 16% this year and 4% during 2014. At today’s 1,475p share price GlaxoSmithKline trades on a forward P/E rating of just over 16 for 2017 and yields a dividend of 5.4% covered just over once by forward earnings. That’s a fair valuation for a defensive business with reasonable forward growth prospects.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

An Important Update From The Motley Fool UK

The future of Motley Fool UK is here.

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s how much to put in your ISA if you hope for passive income of £21,000

With a diversified portfolio of high quality shares and a disciplined investment mindset, Mark Hartley outlines his passive income strategy.

Read more »

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing Articles

Here’s how someone could start buying shares for the price of a weekend break

Is it really possible to start buying shares for the cost of a quick getaway? Our writer explains how it…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 top growth shares to consider on the London Stock Exchange

There are plenty of UK stocks to buy that have potential long runways of growth. Here, our writer highlights two…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£20k invested in a Stocks and Shares ISA this time last year is now worth…

What has 12 months meant for the value of a Stocks and Shares ISA? That depends on how it has…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

While everyone’s piling into AI infrastructure stocks like Micron and SanDisk, consider these out-of-favour Nasdaq 100 names

There’s very little interest in these Nasdaq-listed AI stocks right now despite the fact they’re generating impressive growth. Could this…

Read more »

Workers at Whiting refinery, US
Dividend Shares

Here’s why 2026 has been bumpy for the BP share price

The BP share price has had a good 2026, rising 24% so far. However, ever since the US attacked Iran…

Read more »

A beach at sunset where there is an inscription on the sand "Breathe Deeeply".
Investing Articles

How oil price volatility is impacting stock market sentiment — and how to prepare

As the Middle East crisis deepens, oil price shocks are sending ripples through global stock markets. Mark Hartley considers a…

Read more »